In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Northstar's Buzz

Executive Summary

The hottest clinical space in medical devices may very well be stroke and the hottest technology area could be neurostimulation. Northstar combines both opportunities with an innovative system that addresses a largely un-addressed market--chronic stroke--by stimulating the cortex of the brain. And as promising as this therapy is, it may only be the tip of the iceberg for Northstar

You may also be interested in...



CoAxia's New Path in Stroke

If the 1990s was the decade of the heart, this was supposed to be the decade of the brain. But the tremendous market for stroke device companies has never quite materialized in part because stroke treatment is so elusive. That elusive nature of therapy has led also to unclear technology solutions, complex regulatory paths, and challenging adoption models. CoAxia is staking its claim with a development and clinical trials strategy that departs from those of other stroke start-ups, aiming to prove clinical efficacy in its complex trials.

CoAxia's New Path in Stroke

If the 1990s was the decade of the heart, this was supposed to be the decade of the brain. But the tremendous market for stroke device companies has never quite materialized in part because stroke treatment is so elusive. That elusive nature of therapy has led also to unclear technology solutions, complex regulatory paths, and challenging adoption models. CoAxia is staking its claim with a development and clinical trials strategy that departs from those of other stroke start-ups, aiming to prove clinical efficacy in its complex trials.

Depression Bolsters the Neuromodulation Market

More than a decade ago, venture capitalists identified neurostimulation as a fertile new field for investment, but efforts to date have produced more disappointments than results. The losing streak appears to be over: the FDA recently cleared Neuronetics to begin selling its NeuroStar TMS system for treatment-resistant depression. Meanwhile, Northstar Neuroscience has received FDA approval for the second study of its Renova cortical stimulation device for treating major depressive disorder.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel